AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2024
Jan 4, 2024
31801_dirs_2024-01-04_9f355e69-0d00-4a68-944e-3774c0eb7f30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-01-02
Reporting Person: Martin Samuel Bates (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-02 | Common Stock | M | 10750 | $2.78 | Acquired | 35128 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Incentive Stock Option (Right to Buy) | $2.78 | M | 10750 | Disposed | 2029-06-19 | Common Stock (10750) | Direct |
Footnotes
F1: As of June 19, 2023, the option is fully vested.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Capital/Financing Update
2026
Apr 2
Capital/Financing Update
2026
Apr 1
Major Shareholding Notification
2026
Mar 26